甲磺酸伊马替尼治疗复发或转移胃肠间质瘤35例.pdfVIP

中国综合临床2012 年5 月第 28 卷第5 期 Clinical Medicine of Chin岖.Mav 2012. Vol. 28 .No. 5 . 517 . ·论著· 甲磺酸伊马替尼治疗复发或转移 胃肠间质瘤 35 例 高伟薛春燕王雅杰 I 摘要] 目的 探讨甲磺酸伊马替尼治疗复发或转移胃肠问质瘤的疗效。方法 对我院2007 年 1 月至2010 年2 月收治的 35 例经甲磺酸伊马替尼治疗的复发或转移胃肠间质瘤患者的临床资料进行回 顾性分析。结果 服药3 个月:完全缓解 1 例( 2.9% ， 1/35) ，部分缓解 16 例(45.7% ， 16/35) ，稳定 18 例(5 1. 4% ， 18/35) ，进展。例，临床获益率 l∞% (35/35) 0 2 年生存率 97.1% ， 2 年元进展生存率 82.9% 。结论 甲磺酸伊马替尼治疗复发或转移胃肠间质瘤具有较好的治疗效果且安全可靠。 {关键词] 胃肠间质瘤; 甲磺酸伊马替尼; 复发; 转移 TreatJDent of recurrent or metastatic gastrointes血aI stromal tumors 咧th 恤a血ibm町Iate of 3S ca皿 report GAO Wei , XUE Chu时剧，阳NG Y，α-j;比 Departm.ent 01 Oncology ， 辅liated Changhai JJ，呻italol Second Militalγ Medical University ,Shanghai 2ω433 ， China Corresponding author: WANG Ya-ji陀， Ernail:y句iiewaiJ459@ 163. com [ Abstract) Objective To investigate the effects of imatinib mesylate on recurrent or metastatic gastrointestinal 5tromal tumor. Meth创Is Thi此y-five c皑白 of patients with recurrent or metastatic gastrointestinal stromal tumors treated with Imatinib mesylate from Janu町2∞7 to February 2010 in our hospital were analyzed retrospectively. Resul钮.After treated with Imatinib mesylate for 3 months ,complete remission rate w.描 2.9% ( 1135) ,partial remission rate was 45. 7% ( 16/35) ,stable disease rate was 5 1. 4% ( 18/35)and progressive ra协 was 0; c1inical benefit rate was 1∞%. The 2-year overalI survival rate w回 97. 1 % . The 2-year progression free survival w田 82. 9% . Conclnsion lmatinib mesylate is effective for recurrent or metastatic gastrointestinal stromal tumors and the treatment is safe and reliable. [Key wor也) G酬。intestinal stromal tumor; Imatinib mesylate; Recurrence; Metastasis 胃肠间质瘤 (gastrointestinal stromal tumors , 2 月住院患者中资料完整的术后复发或转移性 GIST GIST) 是胃肠道最常见的间叶组织来源肿瘤(IJ 。此 患者35